EHA 2016: SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients

EHA 2016: SGN-CD33A with hypomethylating therapy produces high remission rates among older AML patients

User Photo
VJHemOnc

4 years
385 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which produces high remission rates among older patients with AML at the 2016 Annual Meeting of the European Association of Hematology (EHA), held in Copenhagen, Denmark.
Up Next Autoplay